Management of essential thrombocythemia.

@article{Cervantes2011ManagementOE,
  title={Management of essential thrombocythemia.},
  author={Francisco Cervantes},
  journal={Hematology. American Society of Hematology. Education Program},
  year={2011},
  volume={2011},
  pages={
          215-21
        }
}
Essential thrombocythemia (ET) is a Philadelphia chromosome (Ph)-negative myeloproliferative neoplasm (MPN) characterized by thrombocytosis and megakaryocytic hyperplasia of the bone marrow, with presence of the JAK2 V617F mutation in 50%-60% of patients. ET evolves to myelofibrosis in a minority of cases, whereas transformation to acute leukemia is rare and increases in association with the use of certain therapies. Survival of ET patients does not substantially differ from that of the general… CONTINUE READING

Citations

Publications citing this paper.
SHOWING 1-10 OF 18 CITATIONS

New Strategies in Myeloproliferative Neoplasms: The Evolving Genetic and Therapeutic Landscape.

  • Clinical cancer research : an official journal of the American Association for Cancer Research
  • 2016
VIEW 1 EXCERPT
CITES BACKGROUND

References

Publications referenced by this paper.
SHOWING 1-10 OF 48 REFERENCES